BRVE - Braveheart Bio, Inc.

Braveheart Bio to Participate in Stifel Cardiometabolic Forum

SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Stifel Virtual Cardiometabolic Forum, being held September 30. Management will participate in a fireside chat on Wednesday, September 30, 2026, at 12:30 p.m. EDT.

Sep 16, 2026 12:30 PM • globenewswire.com

Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effect to Braveheart Bio's Initial Public Offering, Expected to Support Advancement of BHB-1893 Through Late-Stage Clinical Development SAN FRANCISCO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases, today reported unaudited financial results for the second quarter ended June 30, 2026, and provided a business update.

Sep 08, 2026 12:03 PM • globenewswire.com

Braveheart Bio to Participate in Cantor Global Healthcare Conference

SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Cantor Global Healthcare Conference, being held September 9-11 in New York, NY.

Sep 01, 2026 12:30 PM • globenewswire.com

Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?

The transaction involved 27,777 shares acquired for ~$500,000 on August 7, 2026. The acquisition increased the total equity position by 5%, resulting in a 0.87% ownership stake.

Aug 10, 2026 11:39 AM • fool.com

Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?

The transaction involved 83,333 shares with an estimated value of ~$1.5 million as of the August 7, 2026 market close. Director Viehbacher increased his direct equity holdings by 16% through this acquisition.

Aug 10, 2026 11:20 AM • fool.com

Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?

Murdoch exercised options at $18 per share, increasing his total beneficial ownership to ~8 million shares valued at $161 million, representing a 13% stake.

Aug 10, 2026 10:51 AM • fool.com

Braveheart Bio (NASDAQ:BRVE) Director Purchases $999,990.00 in Stock

Braveheart Bio, Inc. (NASDAQ: BRVE - Get Free Report) Director David Charles Lubner purchased 55,555 shares of the stock in a transaction dated Friday, August 7th. The shares were acquired at an average cost of $18.00 per share, with a total value of $999,990.00. Following the acquisition, the director directly owned 55,555 shares in the company,

Aug 10, 2026 01:24 AM • defenseworld.net

Braveheart Bio (NASDAQ:BRVE) CFO Buys $499,986.00 in Stock

Braveheart Bio, Inc. (NASDAQ: BRVE - Get Free Report) CFO James Paul Rickey bought 27,777 shares of the company's stock in a transaction on Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $499,986.00. Following the completion of the transaction, the chief financial officer owned

Aug 10, 2026 01:24 AM • defenseworld.net

Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced the closing of its upsized initial public offering of an aggregate of 24,437,500 shares of its common stock at an initial public offering price of $18.00 per share, including the full exercise by the underwriters of their option to purchase 3,187,500 additional shares. All shares of common stock were offered by Braveheart Bio.

Aug 07, 2026 12:05 PM • globenewswire.com

Braveheart Bio Announces Pricing of Upsized Initial Public Offering

SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced the pricing of its upsized initial public offering of 21,250,000 shares of its common stock at a public offering price of $18.00 per share. The shares are expected to begin trading on the Nasdaq Global Market on August 6, 2026 under the ticker symbol “BRVE.” The offering is expected to close on August 7, 2026, subject to the satisfaction of customary closing conditions. All shares of common stock are being offered by Braveheart Bio.

Aug 05, 2026 06:33 PM • globenewswire.com

Braveheart Bio Readies $300 Million IPO Plan

Braveheart Bio is targeting a $300 million IPO to advance BHB-1893, a promising HCM treatment. BRVE's candidate showed an 86% complete response rate in Phase 2 Chinese trials; Phase 3 trials are planned for 2026–2027. Strong management, top-tier investor backing (including Fidelity's $75 million indication), and substantial de-risking support the premium $775 million proposed enterprise value.

Jul 31, 2026 05:03 AM • seekingalpha.com

Braveheart Bio initiated with an Overweight at Cantor Fitzgerald

$40.00 (was $27.44)

Olivia Brayer Saunders · Cantor Fitzgerald

Aug 31, 2026 06:13 AM • TheFly

Braveheart Bio initiated with a Buy at Jefferies

$48.00 (was $27.44)

Jefferies

Aug 31, 2026 05:00 AM • TheFly

Braveheart Bio initiated with a Buy at Stifel

$45.00 (was $27.44)

James Condulis · Stifel Nicolaus

Aug 31, 2026 04:58 AM • TheFly

Braveheart Bio initiated with a Buy at Goldman Sachs

$48.00 (was $27.44)

Goldman Sachs

Aug 31, 2026 04:32 AM • TheFly